Postmenopausal osteoporosis
Drug research and approvals for postmenopausal osteoporosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 25 studies of postmenopausal osteoporosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 4 authorised medicines for it.
- Recruiting worldwide: 25
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 4
- Effects of Sensorimotor Balance Training vs Digitally Augmented Core Stabilization in Women With OsteoporosisNCT07875894 · Not applicable · Riphah International University · starts Oct 19, 2026
- Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?NCT07677072 · Not reported · Kanuni Sultan Suleyman Training and Research Hospital · starts May 15, 2026
- MicroRNA and Markers and Therapeutic Response to Romosozumab and Abaloparatide in Postmenopausal OsteoporosisNCT07616401 · Not applicable · Istituto Auxologico Italiano · starts Aug 31, 2025
- A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing RegimensNCT07579936 · Phase 2 · Shenzhen Salubris Pharmaceuticals Co., Ltd. · starts Apr 30, 2026
- The Comparison of Ibandronate and Zoledronic Acid After Denosumab DiscontinuationNCT07406685 · Phase 4 · National Taiwan University Hospital · starts Aug 20, 2026
- Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal FemalesNCT07365514 · Phase 1 · University of Connecticut · starts Jul 1, 2026
- Romosozumab and Denosumab, Alone or Combined, in Postmenopausal OsteoporosisNCT07283887 · Phase 4 · National Taiwan University Hospital · starts Dec 3, 2025
- Effect of Mechanical Loading and Bone Loss on Motor Neuron Activity-H-Reflex RelationshipNCT07253493 · Not applicable · Istanbul Physical Medicine Rehabilitation Training and Research Hospital · starts Nov 18, 2025
- COMPASS - COpenhagen MenoPAuSe StudyNCT07254429 · Phase 2 · Martin Blomberg Jensen · starts Oct 2, 2025
Approved 14
- DenosumabTumor necrosis factor ligand superfamily member 11 inhibitor
- Risedronic acidFarnesyl diphosphate synthase inhibitor
- RomosozumabSclerostin inhibitor
- Zoledronic acidFarnesyl diphosphate synthase inhibitor
- Alendronic acidFarnesyl diphosphate synthase inhibitor
- Ibandronic acidFarnesyl diphosphate synthase inhibitor
- RaloxifeneEstrogen receptor beta modulator
- AbaloparatideParathyroid hormone receptor agonist
- Parathyroid hormoneParathyroid hormone receptor agonist
- Calcitonin salmonCalcitonin receptor agonist
- Ranelic acid
- BazedoxifeneEstrogen receptor modulator
- Estrogens, conjugatedEstrogen receptor agonist
- LasofoxifeneEstrogen receptor modulator
Phase 3 9
- CholecalciferolVitamin D receptor agonist
- Calcium carbonate
- ErgocalciferolVitamin D receptor agonist
- OdanacatibCathepsin K inhibitor
- ArzoxifeneEstrogen receptor modulator
- CalcitoninCalcitonin receptor agonist
- Menatetrenone
- LidocaineSodium channel alpha subunit blocker
- AlfacalcidolVitamin D receptor agonist
Phase 2 6
- Teriparatide acetateParathyroid hormone receptor agonist
- DeferasiroxIron chelating agent
- Phytonadione
- Sodium fluoride
- Medronic acid
- Encaleret
Phase 1 or earlier 6
- CalcitriolVitamin D receptor agonist
- SMC021Calcitonin receptor agonist
- BlosozumabSclerostin inhibitor
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- DP001Vitamin D receptor agonist
- Minodronic acidFarnesyl diphosphate synthase inhibitor
How its trials ended
314 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 84 whose ending is known, 82% met their primary endpoint, 5% missed it and 13% stopped early.
- Completed, result not reported16753%
- Met its primary endpoint6922%
- Status unknown3210%
- Ongoing3110%
- Stopped: other or unclear83%
- Missed its primary endpoint41%
- Stopped: enrollment or feasibility21%
- Stopped: safety1<1%
| Oct 16, 2009 | Vantavo (previously Alendronate sodium and colecalciferol, MSD)Alendronic acid; colecalciferol | Organon N.V. | EMA ↗ |
| Apr 17, 2009 | ConbrizaBazedoxifene | Pfizer Europe MA EEIG | EMA ↗ |
| Jan 4, 2007 | AdrovanceAlendronic acid; colecalciferol | Organon N.V. | EMA ↗ |
| Aug 24, 2005 | FosavanceAlendronic acid; colecalciferol | Organon N.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA